BioMedNewsBreaks

WednesdayJun 03, 2026 12:23 pm

BioMedNewsBreaks — VolitionRx Ltd. (NYSE American: VNRX) Expands Patent Portfolio with Ebola Triage Application

VolitionRx Limited (NYSE American: VNRX) announced the filing of a strategic patent application covering the use of its proprietary Nu.Q technology for triaging and monitoring patients suspected of having contracted the Ebola virus. The application builds on the company's existing Nu.Q(R) NETs test, which measures circulating nucleosomes and neutrophil extracellular traps as early indicators of hyper-inflammation associated with septic shock and mortality. Volition said its CE-Marked automated Nu.Q NETs assay and recently developed finger-prick lateral flow detection prototype could provide a low-cost bedside triage solution during Ebola outbreaks, particularly in resource-constrained regions. The company is seeking partnerships with global health organizations, pharmaceutical developers, NGOs and distribution partners to support field…

Continue Reading

WednesdayJun 03, 2026 9:50 am

BioMedNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Drug Delivery and Platform-Based Biotech Innovation

Oncotelic Therapeutics (OTCQB: OTLC) was featured in a BioMedWire editorial exploring how biotechnology companies are increasingly leveraging advanced drug-delivery technologies, nanotechnology platforms and artificial intelligence to enhance existing therapies and expand treatment opportunities. The article highlights Oncotelic’s Sapu003 program, Deciparticle(TM) platform and PDAOAI initiative as part of a broader industry trend toward scalable, multi-application biotechnology platforms capable of supporting oncology and rare disease programs. The editorial also discusses developments from CytoDyn Inc. (OTCQB: CYDY), which is advancing leronlimab for oncology indications; Revolution Medicines Inc. (NASDAQ: RVMD), which reported positive Phase 3 results for daraxonrasib in pancreatic cancer; Moderna Inc. (NASDAQ:…

Continue Reading

TuesdayJun 02, 2026 2:39 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Advanced Cancer Drug Delivery Technologies 

Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial examining how biotechnology companies are increasingly focusing on advanced drug delivery technologies to enhance the effectiveness of existing cancer therapies. The article highlights growing industry interest in nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic approaches designed to improve bioavailability, systemic exposure, tolerability and dosing consistency. The editorial notes that Oncotelic is advancing its Sapu003 program and Deciparticle(TM) platform as part of a broader trend toward nanotechnology-enabled drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy focuses on developing platform technologies with potential applications across multiple oncology and rare disease indications rather than relying on a single therapeutic…

Continue Reading

TuesdayJun 02, 2026 1:24 pm

BioMedNewsBreaks — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Engages Stocks.news for Investor Relations Services 

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising.  Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, announced that it has entered into an investor relations and consulting services agreement with Stocks.news through IR Agency LLC beginning June 8, 2026. Under the six-month agreement, the agency will provide services including company profile creation, media distribution, digital community development, news marketing and lead generation campaigns for a fee of US$250,000. Quantum said IR Agency LLC is arm’s-length to the company and holds no direct or indirect equity interest in its securities.  To view the full press release,…

Continue Reading

TuesdayJun 02, 2026 12:54 pm

BioMedNewsBreaks — Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) Completes GMP Production Run of 5mg Psilocybin Drug Product 

This article has been disseminated on behalf of Optimi Health Corp. and may include paid advertising.  Optimi Health (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, announced the completion of a GMP production run of its 5mg psilocybin finished drug product. The capsules use the same formulation currently prescribed to patients in Australia for treatment-resistant depression, with additional product from the production run designated for upcoming clinical research in the United States and clinical trials in Europe. The company said all stages of manufacturing were completed in-house at its Health Canada-licensed facility, including biomass cultivation, active pharmaceutical ingredient extraction, encapsulation and packaging. Optimi said its vertically integrated platform…

Continue Reading

TuesdayJun 02, 2026 10:10 am

BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Reports Phase 2 HARMONIC Trial Data Supporting LP-300 in EGFR-Mutant Lung Cancer

Lantern Pharma (NASDAQ: LTRN), an AI-driven precision oncology company, reported updated Phase 2 HARMONIC trial data showing that LP-300, in combination with carboplatin and pemetrexed, demonstrated a progression-free survival benefit that increased with treatment duration in patients with EGFR Exon 21 L858R-mutant non-small cell lung cancer who had progressed following TKI therapy. The emerging data showed a median progression-free survival of 8.9 months among L858R patients treated through up to six cycles, compared with 8.4 months across the overall L858R cohort, while maintaining what the company described as an exceptionally clean safety and tolerability profile, supporting a recently FDA-cleared protocol…

Continue Reading

TuesdayJun 02, 2026 10:00 am

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire Podcast

This article has been disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured on the latest episode of The BioMedWire Podcast, where co-founder and executive co-chair Anthony Durkacz discussed the company’s lead drug candidate, Lucid-MS. Durkacz said the therapy is being developed to address mobility loss associated with multiple sclerosis by targeting nerve damage, an area he believes remains unmet by currently available treatments. Durkacz also discussed Quantum BioPharma’s commercial alcohol metabolism product, unbuzzd(TM), which is designed to accelerate blood…

Continue Reading

TuesdayJun 02, 2026 9:00 am

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Study Shows Portable ECG Device Can Help Identify Heart Attack Risk

HeartBeam (NASDAQ: BEAT) a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced that a peer-reviewed article in JACC: Advances demonstrated that a risk prediction algorithm incorporating the credit card-sized HeartBeam ECG device can accurately identify heart attack risk in patients presenting with chest pain. HeartBeam said the proof-of-concept study evaluated 184 patients and found that the algorithm achieved an “area under the curve” (“AUC”) of 86.5% using a single HeartBeam ECG reading combined with patient risk factors and symptoms, rising to 92.9% when a personal, symptom-free baseline ECG was available for comparison. The company said…

Continue Reading

MondayJun 01, 2026 2:15 pm

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Advances Delivery-Focused Oncology Platform Amid Growing Interest in Drug-Delivery Technologies

Oncotelic Therapeutics (OTCQB: OTLC) is advancing its Sapu003 program and Deciparticle platform as part of a strategy focused on improving the delivery, bioavailability and therapeutic consistency of oncology treatments. As biotechnology companies increasingly explore ways to enhance the performance of existing therapies rather than developing entirely new compounds, Oncotelic is leveraging nanotechnology-enabled drug-delivery systems and pharmacokinetic optimization to potentially improve therapeutic outcomes while reducing development risk. The company's approach aligns with broader industry trends favoring advanced delivery technologies that may offer faster development timelines and expanded commercial opportunities. The company is also pursuing a platform-based model through Deciparticle and its AI-enhanced PDAOAI biomedical infrastructure initiative, positioning itself at the intersection of oncology, nanomedicine and artificial intelligence. Growing…

Continue Reading

MondayJun 01, 2026 10:00 am

BioMedNewsBreaks – LIXTE Biotechnology Holdings Inc. (NASDAQ: LIXT) Shifts Focus to AI Energy Infrastructure, Adds Denham Capital Founder to Board

LIXTE Biotechnology Holdings (NASDAQ: LIXT) announced a strategic transformation into an AI energy infrastructure equipment and services platform focused on supporting the growing power demands of artificial intelligence and hyperscale data centers. As part of the transition, Stuart D. Porter, founder, managing partner, CEO and chief investment officer of Denham Capital Management LP, has joined the company's board of directors. LIXTE said its strategy will target power equipment and service solutions for AI data-center campuses, distributed power systems and advanced generation technologies, while it seeks a strategic acquisition partner for its clinical-stage pharmaceutical and med-tech operations focused on cancer treatments.…

Continue Reading